Novo Nordisk is reducing the price of its weight loss drug Wegovy through a new direct-to-consumer pharmacy called NovoCare, making it more accessible for patients without insurance.

Amgen has launched two pivotal late-stage trials for MariTide, an experimental weight loss drug aimed at entering the growing obesity treatment market, competing against other products from Novo Nordisk and Eli Lilly.

Eli Lilly has introduced higher-dose vials of its weight loss drug Zepbound at reduced prices to improve access for uninsured patients and those on Medicare, amidst rising demand and an end to the drug's shortage.

Several companies saw significant stock price movements in the premarket trading session, with notable declines for Hims & Hers Health and Chegg, amid earnings reports and new product launches by firms like Eli Lilly and Keurig Dr Pepper.

Hims & Hers Health experienced a significant 28% drop in shares following disappointing financial results, raised concerns over its weight loss business, and has decided to discontinue some products due to supply resolution.